Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России, Москва, Россия dmitry_trukhan@mail.ru
Список исп. литературыСкрыть список 1. Тарасова Л.В., Трухан Д.И. Лекарственная безопасность в гастроэнтерологии. Экспериментальная и клиническая гастроэнтерология. 2013;(4):81-7. https://elibrary.ru/item.asp?id=21440231 Tarasova L.V., Trukhan D.I. Drug safety in gastroenterology. Experimental and clinical gastroenterology. 2013;(4):81-7. https://elibrary. ru/item.asp?id=21440231 (in Russian) 2. Трухан Д.И. Рациональная фармакотерапия в реальной клинической практике сквозь призму мультиморбидности и лекарственной безопасности. Клинический разбор в общей медицине. 2020;(2):29-39. DOI: 10.47407/kr2020.1.2.00015 Truhan D.I. Rational pharmacotherapy in real clinical practice through the prism of multimorbidity and drug safety. Clinical analysis in general medicine. 2020;(2):29-39. DOI: 10.47407/kr2020.1.2.00015 (in Russian). 3. Трухан Д.И., Коншу Н.В. Рациональная фармакотерапия в клинике внутренних болезней сквозь призму мультиморбидности и лекарственной безопасности. Справочник поликлинического врача. 2019;(2):10-8. https://www.elibrary.ru/item.asp?id=44162870 Trukhan D.I., Konshu N.V. Rational pharmacotherapy in the clinic of internal diseases through the prism of multimorbidity and drug safety. Handbook for Practitioners Doctors. 2019;(2):10-8. https://www.elibrary.ru/item.asp?id=44162870 (in Russian). 4. Ивашкин В.Т., Маев И.В., Царьков П.В. и др. Диагностика и лечение язвенной болезни у взрослых (Клинические рекомендации Российской гастроэнтерологической ассоциации, Российского общества колоректальных хирургов и Российского эндоскопического общества). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(1):49-70. DOI: 10.22416/1382-4376-2020-30-1-49-70 Ivashkin V.T., Maev I.V., Tsar’kov P.V. et al. Diagnosis and Treatment of Peptic Ulcer in Adults (Clinical Guidelines of the Russian Gastroenterological Association, Russian Society of Colorectal Surgeons and the Russian Endoscopic Society). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(1):49-70. DOI: 10.22416/1382-4376-2020-30-1-49-70 (in Russian). 5. Ивашкин В.Т., Маев И.В., Трухманов А.С. и др. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению гастроэзофагеальной рефлюксной болезни. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(4):70-97. DOI: 10.22416/1382-4376-2020-30-4-70-97 Ivashkin V.T., Maev I.V., Trukhmanov A.S. et al. Recommendations of the Russian Gastroenterological Association in Diagnosis and Treatment of Gastroesophageal Refl ux Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(4):70-97. DOI: 10.22416/1382-4376-2020-30-4-70-97 (in Russian). 6. Novotny M, Klimova B, Valis M. PPI Long Term Use: Risk of Neurological Adverse Events? Front Neurol 2019;(9):1142. DOI: 10.3389/ fneur.2018.01142 7. Salvo EM, Ferko NC, Cash SB et al. Umbrella review of 42 systematic reviews with meta-analyses: the safety of proton pump inhibitors. Aliment Pharmacol Ther 2021;54(2):129-43. DOI: 10.1111/apt.16407 8. Chinzon D, Domingues G, Tosetto N, Perrotti M. Safety of long-term proton pump inhibitors: facts and myths. Arq Gastroenterol 2022;59(2):219-25. DOI: 10.1590/S0004-2803.202202000-40 9. Thurber KM, Otto AO, Stricker SL. Proton pump inhibitors: Understanding the associated risks and benefits of long-term use. Am J Health Syst Pharm 2023;80(8):487-94. DOI: 10.1093/ajhp/zxad009 10. Maideen NMP. Adverse Effects Associated with Long-Term Use of Proton Pump Inhibitors. Chonnam Med J 2023;59(2):115-27. DOI: 10.4068/cmj.2023.59.2.115 11. Yibirin M, De Oliveira D, Valera R et al. Adverse effects associated with proton pump inhibitor use. Cureus 2021;13(1):e12759. DOI: 10.7759/cureus.12759 12. Kinoshita Y, Ishimura N, Ishihara S. Advantages and disadvantages of long-term proton pump inhibitor use. J Neurogastroenterol Motil 2018;24:182-96. DOI: 10.5056/jnm18001 13. Singh A, Cresci GA, Kirby DF. Proton Pump Inhibitors: Risks and Rewards and Emerging Consequences to the Gut Microbiome. Nutr Clin Pract 2018;33(5):614-24. DOI: 10.1002/ncp.10181 14. Naito Y, Kashiwagi K, Takagi T et al. Intestinal Dysbiosis Secondary to Proton-Pump Inhibitor Use. Digestion 2018;97(2):195-204. DOI: 10.1159/000481813 15. Tawam D, Baladi M, Jungsuwadee P et al. The Positive Association between Proton Pump Inhibitors and Clostridium Difficile Infection. Innov Pharm 2021;12(1):10.24926/iip.v12i1.3439. DOI: 10.24926/iip.v12i1.3439 16. Marcum ZA, Vande Griend JP, Linnebur SA. FDA drug safety communications: a narrative review and clinical considerations for older adults. Am J Geriatr Pharmacother 2012;10(4):264-71. DOI: 10.1016/ j.amjopharm.2012.05.002 17. Kochan TJ, Foley MH, Shoshiev MS et al. Updates to Clostridium difficile Spore Germination. J Bacteriol 2018;200(16):e00218-18. DOI: 10.1128/JB.00218-18 18. Wetzel D, McBride SM. The impact of pH on Clostridioides difficile sporulation and physiology. Appl Environ Microbiol 2020;86(4): e02706-e02719. DOI: 10.1128/AEM.02706-19 19. D’Silva KM, Mehta R, Mitchell M et al. Proton pump inhibitor use and risk for recurrent Clostridioides difficile infection: a systematic review and meta-analysis. Clin Microbiol Infect 2021;(27):697-703. DOI: 10.1016/j.cmi.2021.01.008 20. Trifan A, Stanciu C, Girleanu I et al. Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysis. World J Gastroenterol 2017;23(35):6500-15. DOI: 10.3748/wjg.v23.i35.6500 21. Inghammar M, Svanström H, Voldstedlund M et al. Proton-Pump Inhibitor Use and the Risk of Community-Associated Clostridium difficile Infection. Clin Infect Dis 2021;72(12):e1084-e1089. DOI: 10.1093/ cid/ciaa1857 22. Azab M, Doo L, Doo DH et al. Comparison of the Hospital-Acquired Clostridium difficile Infection Risk of Using Proton Pump Inhibitors versus Histamine-2 Receptor Antagonists for Prophylaxis and Treatment of Stress Ulcers: A Systematic Review and Meta-Analysis. Gut Liver 2017;11(6):781-8. DOI: 10.5009/gnl16568 23. Fohl AL, Regal RE. Proton pump inhibitor-associated pneumonia: not a breath of fresh air after all? World J Gastrointest Pharmacol Ther 2011;(2):17-26. DOI: 10.4292/wjgpt.v2.i3.17 24. Wang CH, Li CH, Hsieh R et al. Proton pump inhibitors therapy and the risk of pneumonia: a systematic review and meta-analysis of randomized controlled trials and observational studies. Expert Opin Drug Saf 2019;18(3):163-72. DOI: 10.1080/14740338.2019.1577820 25. Nguyen PA, Islam M, Galvin CJ et al. Meta-analysis of proton pump inhibitors induced risk of community-acquired pneumonia. Int J Qual Health Care 2020;32(5):292-9. DOI: 10.1093/intqhc/mzaa041 26. Xun X, Yin Q, Fu Y et al. Proton pump inhibitors and the risk of community-acquired pneumonia: an updated meta-analysis. Ann Pharmacother 2022;56(5):524-32. DOI: 10.1177/10600280211039240 27. Giuliano C, Wilhelm SM, Kale-Pradhan PB. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert Rev Clin Pharmacol 2012;5(3):337-44. DOI: 10.1586/ecp.12.20 28. Lambert AA, Lam JO, Paik JJ et al. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One 2015;10(6):e0128004. DOI: 10.1371/journal.pone.0128004 29. Othman F, Crooks CJ, Card TR. Community acquired pneumonia incidence before and after proton pump inhibitor prescription: population based study. BMJ 2016 Nov 15;355:i5813. DOI: 10.1136/bmj.i5813 30. Zirk-Sadowski J, Masoli JA, Delgado J et al. Proton-Pump Inhibitors and Long-Term Risk of Community-Acquired Pneumonia in Older Adults. J Am Geriatr Soc 2018;66(7):1332-8. DOI: 10.1111/jgs.15385 31. Ble A, Zirk-Sadowski J, Masoli JA. Reply to: Proton Pump Inhibitors and Long-term Risk of Community-acquired Pneumonia in Older Adults. J Am Geriatr Soc 2018;66(12):2428-9. DOI: 10.1111/jgs.15637 32. Maret-Ouda J, Panula J, Santoni G et al. Proton pump inhibitor use and risk of pneumonia: a self-controlled case series study. J Gastroenterol 2023;58(8):734-40. DOI: 10.1007/s00535-023-02007-5 33. Charpiat B, Bleyzac N, Tod M. Proton Pump Inhibitors are Risk Factors for Viral Infections: Even for COVID-19? Clin Drug Investig 2020;40(10):897-9. DOI: 10.1007/s40261-020-00963-x 34. Fatima K, Almas T, Lakhani S et al. The use of proton pump inhibitors and COVID-19: a systematic review and meta-analysis. Trop Med Infect Dis 2022;(7):37. DOI: 10.3390/tropicalmed7030037 35. Almario CV, Chey WD, Spiegel BMR. Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors. Am J Gastroenterol 2020;115(10):1707-15. DOI: 10.14309/ajg.0000000000000798 36. Li GF, An XX, Yu Y et al. Do proton pump inhibitors influence SARS-CoV-2 related outcomes? A meta-analysis. Gut 2021;70(9):1806-8. DOI: 10.1136/gutjnl-2020-323366 37. Israelsen SB, Ernst MT, Lundh A et al. Proton Pump Inhibitor Use Is Not Strongly Associated With SARS-CoV-2 Related Outcomes: A Nationwide Study and Meta-analysis. Clin Gastroenterol Hepatol 2021;19(9):1845-54.e6. DOI: 10.1016/j.cgh.2021.05.011 38. Toubasi AA, AbuAnzeh RB, Khraisat BR et al. Proton Pump Inhibitors: Current Use and the Risk of Coronavirus Infectious Disease 2019 Development and its Related Mortality. Meta-analysis. Arch Med Res 2021;52(6):656-9. DOI: 10.1016/j.arcmed.2021.03.004 39. Yan C, Chen Y, Sun C et al. Does Proton Pump Inhibitor Use Lead to a Higher Risk of Coronavirus Disease 2019 Infection and Progression to Severe Disease? a Meta-analysis. Jpn J Infect Dis 2022;75(1):10-5. DOI: 10.7883/yoken.JJID.2021.074 40. Pranata R, Huang I, Lawrensia S et al. Proton pump inhibitor on susceptibility to COVID-19 and its severity: a systematic review and meta-analysis. Pharmacol Rep 2021;73(6):1642-9. DOI: 10.1007/s43440-021-00263-x 41. Kamal F, Khan MA, Sharma S et al. Lack of Consistent Associations Between Pharmacologic Gastric Acid Suppression and Adverse Outcomes in Patients With Coronavirus Disease 2019: Meta-Analysis of Observational Studies. Gastroenterology 2021;160(7):2588-90.e7. DOI: 10.1053/j.gastro.2021.02.028 42. Ramachandran P, Perisetti A, Gajendran M et al. Pre-hospitalization proton pump inhibitor use and clinical outcomes in COVID-19. Eur J Gastroenterol Hepatol 2022;34(2):137-41. DOI: 10.1097/MEG. 0000000000002013 43. Kim HB, Kim JH, Wolf BJ. Acid suppressant use in association with incidence and severe outcomes of COVID-19: a systematic review and meta-analysis. Eur J Clin Pharmacol 2022;78(3):383-91. DOI: 10.1007/s00228-021-03255-1 44. Lespessailles E, Toumi H. Proton Pump Inhibitors and Bone Health: An Update Narrative Review. Int J Mol Sci 2022;23(18):10733. DOI: 10.3390/ijms231810733 45. Insogna KL. The effect of proton pump-inhibiting drugs on mineral metabolism. Am J Gastroenterol 2009;104(Suppl. 2):S2-4. DOI: 10.1038/ajg.2009.44 46. Thong BKS, Ima-Nirwana S, Chin KY. Proton pump inhibitors and fracture risk: a review of current evidence and mechanisms involved. Int J Environ Res Public Health 2019;16(9):1571. DOI: 10.3390/ijerph16091571 47. Yu EW, Bauer SR, Bain PA, Bauer DC. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med 2011;124(6):519-26. DOI: 10.1016/j.amjmed.2011.01.007 48. Targownik LE, Leslie WD, Davison KS et al.; CaMos Research Group. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol 2012;107(9):1361-9. DOI: 10.1038/ajg.2012.200 49. Arj A, Razavi Zade M, Yavari M et al. Proton pump inhibitors use and change in bone mineral density. Int J Rheum Dis 2016;19(9):864-8. DOI: 10.1111/1756-185X.12866 50. Hussain MS, Mazumder T. Long-term use of proton pump inhibitors adversely affects minerals and vitamin metabolism, bone turnover, bone mass, and bone strength. J Basic Clin Physiol Pharmacol 2021;33(5):567-79. DOI: 10.1515/jbcpp-2021-0203 51. Zhang X, Adebayo AS, Wang D et al. PPI-Induced Changes in Plasma Metabolite Levels Influence Total Hip Bone Mineral Density in a UK Cohort. J Bone Miner Res 2023;38(2):326-34. DOI: 10.1002/jbmr.4754 52. Poly TN, Islam MM, Yang HC et al. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies. Osteoporos Int 2019;30(1):103-14. DOI: 10.1007/s00198-018-4788-y 53. Ngamruengphong S, Leontiadis GI, Radhi S et al. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol 2011;106(7):1209-18. DOI: 10.1038/ajg.2011.113 54. Zhou B, Huang Y, Li H et al. Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int 2016;27(1):339-47. DOI: 10.1007/s00198-015-3365-x 55. Liu J, Li X, Fan L et al. Proton pump inhibitors therapy and risk of bone diseases: An update meta-analysis. Life Sci 2019 Feb 1;218:213-23. DOI: 10.1016/j.lfs.2018.12.058 56. Park JH, Lee J, Yu SY et al. Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease. BMC Geriatr 2020;20(1):407. DOI: 10.1186/s12877-020-01794-3 57. Lin SM, Yang SH, Liang CC, Huang HK. Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study. Osteoporos Int 2018;29(1):153-62. DOI: 10.1007/s00198-017-4262-2 58. Desai BV, Qadri MN, Vyas BA. Proton pump inhibitors and osteoporosis risk: exploring the role of TRPM7 channel. Eur J Clin Pharmacol 2022;78(1):35-41. DOI: 10.1007/s00228-021-03237-3 59. Cheng Z, Liu Y, Ma M et al. Lansoprazole-induced osteoporosis via the IP3R- and SOCE-mediated calcium signaling pathways. Mol Med 2022;28(1):21. DOI: 10.1186/s10020-022-00448-x 60. Sobel RE, Bate A, Marshall J et al. Do FDA label changes work? Assessment of the 2010 class label change for proton pump inhibitors using the Sentinel System's analytic tools. Pharmacoepidemiol Drug Saf 2018;27(3):332-9. DOI: 10.1002/pds.4392 61. Sugiyama T. Proton pump inhibitor use and fracture risk: an update of drug safety communication needed? Am J Gastroenterol 2019;114(2):360-1. DOI: 10.14309/ajg.0000000000000053 62. Al-Aly Z, Maddukuri G, Xie Y. Proton pump inhibitors and the kidney: implications of current evidence for clinical practice and when and how to deprescribe. Am J Kidney Dis 2020;75(4):497-507. DOI: 10.1053/j.ajkd.2019.07.012 63. Nochaiwong S, Ruengorn C, Awiphan R et al. The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant 2018;33(2):331-42. DOI: 10.1093/ndt/gfw470 64. Lu S, Zhao J, Chen X et al. Proton pump inhibitor-induced risk of chronic kidney disease is associated with increase of indoxyl sulfate synthesis via inhibition of CYP2E1 protein degradation. Chem Biol Interact 2022 Dec 1;368:110219. DOI: 10.1016/j.cbi.2022.110219 65. Blank ML, Parkin L, Paul C, Herbison P. A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use. Kidney Int 2014;86(4):837-44. DOI: 10.1038/ki.2014.74 66. Torpey N, Barker T, Ross C. Drug-induced tubulo-interstitial nephritis secondary to proton pump inhibitors: experience from a single UK renal unit. Nephrol Dial Transplant 2004;19(6):1441-6. DOI: 10.1093/ndt/gfh137 67. Geevasinga N, Coleman PL, Webster AC, Roger SD. Proton pump inhibitors and acute interstitial nephritis. Clin Gastroenterol Hepatol 2006;(4):597-604. DOI: 10.1016/j.cgh.2005.11.004 68. Simpson IJ, Marshall MR, Pilmore H et al. Proton pump inhibitors and acute interstitial nephritis: report and analysis of 15 cases. Nephrology (Carlton) 2006;(11):381-5. DOI: 10.1111/j.1440-1797.2006.00651.x 69. Härmark L, van der Wiel HE, de Groot MC, van Grootheest AC. Proton pump inhibitor-induced acute interstitial nephritis. Br J Clin Pharmacol 2007;64(6):819-23. DOI: 10.1111/j.1365-2125.2007.02927.x 70. Klepser DG, Collier DS, Cochran GL. Proton pump inhibitors and acute kidney injury: a nested case-control study. BMC Nephrol 2013;(14):150. DOI: 10.1186/1471-2369-14-150 71. Ikuta K, Nakagawa S, Momo K et al. Association of proton pump inhibitors and concomitant drugs with risk of acute kidney injury: a nested case-control study. BMJ Open 2021;11(2):e041543. DOI: 10.1136/bmjopen-2020-041543 72. Antoniou T, Macdonald EM, Hollands S et al. Proton pump inhibitors and the risk of acute kidney injury in older patients: a population-based cohort study. CMAJ Open 2015;3(2):E166-E171. DOI: 10.9778/cmajo.20140074 73. Svanström H, Lund M, Melbye M, Pasternak B. Use of proton pump inhibitors and the risk of acute kidney injury among patients with rheumatoid arthritis: cohort study. Drug Saf 2018;41(8):817-26. DOI: 10.1007/s40264-018-0663-1 74. Sutton SS, Magagnoli J, Cummings TH, Hardin JW. Risk of acute kidney injury in patients with HIV receiving proton pump inhibitors. J Comp Eff Res 2019;8(10):781-90. DOI: 10.2217/cer-2019-0017 75. Yang Y, George KC, Shang WF et al. Proton-pump inhibitors use, and risk of acute kidney injury: a meta-analysis of observational studies. Drug Des Devel Ther 2017;(11):1291-9. DOI: 10.2147/DDDT.S130568 76. Chen G, Ning LJ, Qin Y et al. Acute kidney injury following the use of different proton pump inhibitor regimens: A real-world analysis of post-marketing surveillance data. J Gastroenterol Hepatol 2021;36(1):156-62. DOI: 10.1111/jgh.15151 77. Wu B, Li D, Xu T et al. Proton pump inhibitors associated acute kidney injury and chronic kidney disease: data mining of US FDA adverse event reporting system. Sci Rep 2021;11(1):3690. DOI: 10.1038/ s41598-021-83099-y 78. Hart E, Dunn TE, Feuerstein S, Jacobs DM. Proton Pump Inhibitors and Risk of Acute and Chronic Kidney Disease: A Retrospective Cohort Study. Pharmacotherapy 2019;39(4):443-53. DOI: 10.1002/phar.2235 79. Han CT, Islam MM, Poly TN et al. A Meta-Analysis of Proton Pump Inhibitor Use and the Risk of Acute Kidney Injury: Geographical Differences and Associated Factors. J Clin Med 2023;12(7):2467. DOI: 10.3390/jcm12072467 80. Arora P, Gupta A, Golzy M et al. Proton pump inhibitors are associated with increased risk of development of chronic kidney disease. BMC Nephrol 2016;17(1):112. DOI: 10.1186/s12882-016-0325-4 81. Lazarus B, Chen Y, Wilson FP et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med 2016;176(2):238-46. DOI: 10.1001/jamainternmed.2015.7193 82. Xie Y, Bowe B, Li T et al. Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury. Kidney Int 2017;91(6):1482-94. DOI: 10.1016/j.kint.2016.12.021 83. Klatte DCF, Gasparini A, Xu H et al. Association between proton pump inhibitor use and risk of progression of chronic kidney disease. Gastroenterology 2017;153(3):702-10. DOI: 10.1053/j.gastro.2017.05.046 84. Yang H, Juang SY, Liao KF. Proton pump inhibitors use and risk of chronic kidney disease in diabetic patients. Diabetes Res Clin Pract 2019;147:67-75. DOI: 10.1016/j.diabres.2018.11.019 85. Rodríguez-Poncelas A, Barceló MA, Saez M et al. Duration and dosing of proton pump inhibitors associated with high incidence of chronic kidney disease in population-based cohort. PLoS One 2018;13(10): e0204231. DOI: 10.1371/journal.pone.0204231 86. Guedes JVM, Aquino JA, Castro TLB et al. Omeprazole use and risk of chronic kidney disease evolution. PLoS One 2020;15(3):e0229344. DOI: 10.1371/journal.pone.0229344 87. Zhang XY, He QS, Jing Z et al. Effect of proton pump inhibitors on the risk of chronic kidney disease: A propensity score-based overlap weight analysis using the United Kingdom Biobank. Front Pharmacol 2022 Nov 10;13:949699. DOI: 10.3389/fphar.2022.949699 88. Wu CC, Liao MH, Kung WM, Wang YC. Proton Pump Inhibitors and Risk of Chronic Kidney Disease: Evidence from Observational Studies. J Clin Med 2023;12(6):2262. DOI: 10.3390/jcm12062262 89. Wijarnpreecha K, Thongprayoon C, Chesdachai S et al. Associations of Proton-Pump Inhibitors and H2 Receptor Antagonists with Chronic Kidney Disease: A Meta-Analysis. Dig Dis Sci 2017;62(10):2821-7. DOI: 10.1007/s10620-017-4725-5 90. Peng YC, Lin CL, Yeh HZ et al. Association between the use of proton pump inhibitors and the risk of ESRD in renal diseases: a population-based, case-control study. Medicine (Baltimore) 2016;95(15):e3363 DOI: 10.1097/MD.0000000000003363 91. Xie Y, Bowe B, Li T et al. Proton pump inhibitors and risk of incident CKD and progression to ESRD. J Am Soc Nephrol 2016;27(10):3153-63. DOI: 10.1681/ASN.2015121377 92. Sui W, Miller NL, Gould ER et al. Proton pump inhibitors use and risk of incident nephrolithiasis. Urolithiasis 2022;50(4):401-9. DOI: 10.1007/s00240-022-01326-1 93. Simonov M, Abel EA, Skanderson M et al. Use of Proton Pump Inhibitors Increases Risk of Incident Kidney Stones. Clin Gastroenterol Hepatol 2021;19(1):72-9.e21. DOI: 10.1016/j.cgh.2020.02.053 94. Bapir R, Bhatti KH, Eliwa A et al. Risk of urinary stone formation associated to proton pump inhibitors: A systematic review and metanalysis. Arch Ital Urol Androl 2022;94(4):507-14. DOI: 10.4081/aiua. 2022.4.507 95. Liu W, Wang J, Wang M et al. Association of proton pump inhibitor use with risk of kidney stones: an analysis of cross-sectional data from the US National Health and Nutrition Examination Survey (2007-2018). BMJ Open 2023;13(10):e075136. DOI: 10.1136/bmjopen- 2023-075136 96. Makunts T, Cohen IV, Awdishu L, Abagyan R. Analysis of postmarketing safety data for proton-pump inhibitors reveals increased propensity for renal injury, electrolyte abnormalities, and nephrolithiasis. Sci Rep 2019;9(1):2282. DOI: 10.1038/s41598-019-39335-7